co-stimulation love


from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. The requirement of T cells for two signals in order to become fully activated


Sorry, no etymologies found.


  • Food and Drug Administration´s (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted 13 to 5 to recommend approval of belatacept, a selective co-stimulation blocker, for the prophylaxis of acute rejection in de novo kidney transplant patients.

    American Chronicle

  • Macrophages were treated with noscapine or brominated noscapine analogs at 10, 25 and 50 µM prior to stimulation or co-stimulation with highly purified TLR-ligands (meningococcal LPS, a TLR4-MD-2 ligand and the synthetic lipopetide Pam3CSK4, a TLR2 ligand).

    PLoS ONE Alerts: New Articles

  • This study doesn't conclude that dual influence of IL-4 and TGF-β in presence of TCR stimulation and co-stimulation induces human

    PLoS ONE Alerts: New Articles

  • Grimbacher B (2006) Common variable immunodeficiency: The power of co-stimulation.

    PLoS ONE Alerts: New Articles

  • ORENCIA is a selective co-stimulation modulator of T-cell activation.

    Health News from Medical News Today

  • They also expressed the co-stimulation markers CD80 and CD86, and the maturation marker CD83 at a lower level.

    PLoS ONE Alerts: New Articles

  • Belatacept is a fusion protein designed to be a selective co-stimulation blocker that binds to a specific site on certain cells of the immune system (i.e., antigen presenting cells) to block the second signal necessary to activate naïve T-cells, which coordinate immune-mediated rejection of transplanted organs.

    Health News from Medical News Today

  • Histograms represent the expression of co-stimulation molecules by total DC in control mice (dotted line), total DC (thin lined histogram) and Ag85B-ESAT-6

    PLoS ONE Alerts: New Articles

  • Assessing the surface expression of the CD40, CD80 and CD86 co-stimulation molecules indicated that IC31® only activated Adj

    PLoS ONE Alerts: New Articles

  • -- an internally discovered biologic investigational compound, belatacept, a novel co-stimulation blocker under development to replace cornerstone therapy in solid organ transplantation, which the company expects to submit to the FDA for filing in the first half of 2009; and

    Bristol-Myers Press Release


Log in or sign up to get involved in the conversation. It's quick and easy.